Related Experiment Video
Updated: Apr 4, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Bevacizumab in recurrent glioblastoma: open issues
Enrico Franceschi1, Marco Bartolotti1, Alba A Brandes1
1Department of Medical Oncology, Azienda USL, Bellaria Hospital - IRCCS Institute of Neurological Sciences, Bologna, Italy.
Abstract:
Recurrent glioblastoma represents a challenge in neuro-oncology since the prognosis is poor and current therapeutic options are limited. Bevacizumab has demonstrated activity in this setting in various clinical trials and has been approved by US FDA for the treatment of recurrent glioblastoma. Nevertheless, many issues still exist. In this article, we summarized the principal subjects of controversies that surround bevacizumab and its use in the treatment of recurrent glioblastoma.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers

